Repligen Corp RGEN
We take great care to ensure that the data presented and summarized in this overview for REPLIGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGEN
View all-
Black Rock Inc. New York, NY7.57MShares$861 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$751 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$577 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$218 Million0.53% of portfolio
-
State Street Corp Boston, MA1.62MShares$185 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.4MShares$159 Million1.29% of portfolio
-
Invesco Ltd. Atlanta, GA1.38MShares$157 Million0.03% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.25MShares$142 Million0.47% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.06MShares$121 Million0.02% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.01MShares$114 Million3.75% of portfolio
Latest Institutional Activity in RGEN
Top Purchases
Top Sells
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Transactions at RGEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 10
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
29,111
-4.05%
|
$3,464,209
$119.69 P/Share
|
Sep 10
2025
|
Anthony Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+13.35%
|
$660,000
$33.87 P/Share
|
Sep 03
2025
|
Olivier Loeillot Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,506
-5.37%
|
$290,696
$116.18 P/Share
|
Sep 02
2025
|
Violetta Hughes CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,142
+50.0%
|
-
|
Aug 08
2025
|
Martin D Madaus |
BUY
Open market or private purchase
|
Indirect |
1,800
+50.0%
|
$201,600
$112.13 P/Share
|
May 15
2025
|
Nicolas Barthelemy |
BUY
Grant, award, or other acquisition
|
Direct |
973
+17.97%
|
-
|
May 15
2025
|
Konstantin Konstantinov |
BUY
Grant, award, or other acquisition
|
Direct |
973
+25.16%
|
-
|
May 15
2025
|
Manner Carrie Eglinton |
BUY
Grant, award, or other acquisition
|
Direct |
973
+17.89%
|
-
|
May 15
2025
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
973
+2.84%
|
-
|
May 15
2025
|
Karen A Dawes |
BUY
Grant, award, or other acquisition
|
Direct |
973
+1.05%
|
-
|
May 15
2025
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
973
+14.83%
|
-
|
May 15
2025
|
Margaret Pax |
BUY
Grant, award, or other acquisition
|
Direct |
973
+32.55%
|
-
|
May 15
2025
|
Rohin Mhatre |
BUY
Grant, award, or other acquisition
|
Direct |
973
+19.49%
|
-
|
May 15
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
26,447
-4.09%
|
$3,279,428
$124.55 P/Share
|
Apr 01
2025
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
454
-1.88%
|
$58,112
$128.5 P/Share
|
Mar 17
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
26,756
-2.88%
|
$4,040,156
$151.33 P/Share
|
Mar 17
2025
|
Anthony Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+7.59%
|
$1,230,776
$46.7 P/Share
|
Mar 17
2025
|
Margaret Pax |
BUY
Open market or private purchase
|
Direct |
250
+19.33%
|
$37,500
$150.69 P/Share
|
Mar 13
2025
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-0.72%
|
$24,850
$142.44 P/Share
|
Mar 13
2025
|
James Bylund Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
381
+1.54%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 102K shares |
---|---|
Grant, award, or other acquisition | 44.5K shares |
Open market or private purchase | 2.05K shares |
Payment of exercise price or tax liability | 24.5K shares |
---|---|
Open market or private sale | 107K shares |